JP2023040169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023040169A5 JP2023040169A5 JP2023001554A JP2023001554A JP2023040169A5 JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5 JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- replaced
- asn
- lys
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706406.4 | 2017-04-21 | ||
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706404.9 | 2017-04-21 | ||
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| GB1706452.8 | 2017-04-24 | ||
| JP2019556794A JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Division JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023040169A JP2023040169A (ja) | 2023-03-22 |
| JP2023040169A5 true JP2023040169A5 (enExample) | 2023-10-11 |
| JP7600278B2 JP7600278B2 (ja) | 2024-12-16 |
Family
ID=62235916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| JP2023001554A Active JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (enExample) |
| EP (2) | EP4275696A1 (enExample) |
| JP (2) | JP7209637B2 (enExample) |
| KR (1) | KR102656199B1 (enExample) |
| CN (1) | CN110896606B (enExample) |
| AU (1) | AU2018253962B2 (enExample) |
| CA (1) | CA3059657A1 (enExample) |
| DK (1) | DK3612208T5 (enExample) |
| ES (1) | ES2945433T3 (enExample) |
| IL (1) | IL269895B2 (enExample) |
| PL (1) | PL3612208T3 (enExample) |
| WO (1) | WO2018193122A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) * | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2023503776A (ja) * | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US7884188B2 (en) | 2003-06-02 | 2011-02-08 | Varleigh Immuno Pharmaceuticals (Vip) Ltd | Complement inhibitors |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| EP2061501B1 (en) * | 2006-09-08 | 2015-04-08 | Volution Immuno Pharmaceuticals SA | Method of treating respiratory disorders |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2008113834A2 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| US8563521B2 (en) * | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| EP2331564A4 (en) * | 2008-10-06 | 2013-02-20 | Carolus Therapeutics Inc | PROCESS FOR TREATMENT OF IGNITION |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| US9290736B2 (en) * | 2009-11-04 | 2016-03-22 | Case Western Reserve University | Compositions and methods of treating T cell mediated disorder |
| CA2785612C (en) | 2010-01-08 | 2019-09-10 | Varleigh Immuno Pharmaceuticals (Vip) Ltd. | Ev576 for use in the treatment of viral infections of the respiratory tract |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| GB201410031D0 (en) * | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2016198133A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SMT202100688T1 (it) * | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| WO2016200627A1 (en) * | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP3307316A1 (en) * | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3328885A1 (en) * | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| GB201706406D0 (en) * | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
-
2018
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en not_active Withdrawn
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534220A5 (enExample) | ||
| Kaspar et al. | Future directions for peptide therapeutics development | |
| CN1820734B (zh) | 用抗ErbB2抗体治疗 | |
| TWI436776B (zh) | Ｆｇｆ２１突變體及其用途 | |
| JP2024150674A5 (enExample) | ||
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2023504914A5 (enExample) | ||
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| JP2017538395A5 (enExample) | ||
| AU2020242144B2 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| JP2022546454A5 (enExample) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2023553697A5 (enExample) | ||
| JP2023545707A5 (enExample) | ||
| BRPI0806715A2 (pt) | fab peguilado para abeta | |
| JP2021521781A5 (enExample) | ||
| JP2023500248A5 (enExample) | ||
| JP2020517627A5 (enExample) | ||
| JP2021514354A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| JP2025517100A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| WO2020081786A1 (en) | Exosome-targeting bispecific antibodies | |
| JP2023503472A (ja) | 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 | |
| JP2022530068A5 (enExample) |